F. MHRA Actions, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA
Upon receipt of a serious breach notification, the MHRA will review and assess the notification, and a variety of actions may be taken, depending on the nature of the breach and its potential impact. In general:
1. The GCP Inspectorate checks the serious breach mailbox.
2. Receipt of the notification will be sent and a GCP Inspector will be assigned to review.
3. The Inspector is responsible for reviewing the serious breach.
4. The inspector will decide if:
- the referral only requires to be logged with no further action (the case may be examined during future MHRA inspections).
- further information/investigation/CAPA is required. If insufficient information is provided in the initial notification to assess the impact of the breach, follow-up information will be requested.
- if any other bodies are required to be notified (for example, other competent authorities/EMA, Licensing Division, Clinical Trials Unit (CTU), HRA, Research Ethics Committees, other GxP areas, etc.).
- further actions are required (for example, a referral to the MHRA Inspection Action Group if the issue is critical or trigger an inspection to investigate further).
- referral to CTU for consideration of suspension or termination of a clinical trial authorisation.
- referral to the MHRA Enforcement Unit for consideration of enforcement action, for example, infringement notices, criminal investigation.
- referral to professional bodies, for example, the General Medical Council.
5. Once any/all required actions have been satisfactorily completed, the inspector will close the referral.
Clinical Research News
Prossimi studi clinici
-
Intuitive SurgicalNon ancora reclutamento
-
Bristol-Myers SquibbNon ancora reclutamento
-
University of Alabama at BirminghamNon ancora reclutamentoSpinal Cord DisordersStati Uniti
-
Medical University of ViennaNon ancora reclutamentoAccesso vascolare | Complicazione dell'accesso vascolare | Infezioni da catetere per dialisi | Emodialisi | Complicanza dell'emodialisi | Disfunzione dell'accesso alla dialisi | ESRD (malattia renale allo stadio terminale) | Catetere di dialisiAustria
-
NYU Langone HealthNational Cancer Institute (NCI)Non ancora reclutamentoCancro alla prostataStati Uniti
-
M.D. Anderson Cancer CenterNon ancora reclutamentoAngiosarcoma cutaneoStati Uniti
-
Helwan UniversityNon ancora reclutamento
-
Prevention Strategies, LLCNational Institute on Drug Abuse (NIDA); NORC at the University of ChicagoNon ancora reclutamentoDisturbi correlati all'alcol | Disturbo da uso di tabacco | Uso di marijuana | Disturbi correlati a sostanze
-
Second Affiliated Hospital of Nanchang UniversityBeijing Pearl Biotechnology Limited Liability CompanyReclutamentoCancro polmonare non a piccole celluleCina
-
Ming LiuNon ancora reclutamentoAdenocarcinoma gastrico | Adenocarcinoma della giunzione gastroesofageaCina
-
The First Affiliated Hospital of Soochow UniversityNon ancora reclutamentoTumori della sottomucosa gastrica
-
Peking University First HospitalPeking University Shenzhen HospitalNon ancora reclutamentoPazienti Anziani | Chirurgia del cancro | Gestione mirata della temperatura | Ipotermia, Accidentale | Recupero neurocognitivo ritardatoCina
Clinical Research Jobs
-
United Kingdom - London
-
United States - Reno
-
United States - North Carolina - Durham
-
Poland - Krakow
-
Japan - Tokyo
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
